# PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [7] : A61B 5/0285, 5/0225	A1	(11) International Publication Number: WO 00/47110
		(43) International Publication Date: 17 August 2000 (17.08.00)

(21) International Application Number: PCT/IL00/00089

(22) International Filing Date: 11 February 2000 (11.02.00)

(30) Priority Data:
128482   11 February 1999 (11.02.99)   IL

(71) Applicant (for all designated States except US): ULTRAMIND INTERNATIONAL LTD. [IL/IL]; Jerusalem Technological Park, Building 1, Malcha, 91482 Jerusalem (IL).

(72) Inventors; and
(75) Inventors/Applicants (for US only): SHUSTERMAN, Vladimir [IL/US]; 245 Melwood Avenue, App. 50, Pittsburgh, PA 1521 (US). ROYTVARF, Alex [IL/IL]; Tiomkin 6/11, 75257 Rishon Lezion (IL). ORBACH, Tuvi [IL/IL]; Ultramind International Ltd., Jerusalem Technological Park, Building 1, Malcha, 91482 Jerusalem (IL).

(74) Agent: REINHOLD COHN AND PARTNERS; P.O. Box 4060, 61040 Tel Aviv (IL).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHOD AND DEVICE FOR CONTINUOUS ANALYSIS OF CARDIOVASCULAR ACTIVITY OF A SUBJECT

(57) Abstract

A method for obtaining continuously and non–invasively one or more parameters relating to the cardiovascular system of a subject. The parameters obtainable by the method are systolic blood pressure, diastolic blood pressure, young modulus of an artery, cardiac output, relative changes in vascular resistance, and relative changes in vascular compliance. In accordance with the method, the ratio, κ of the subject's blood flow velocity to the propagation speed of the subject's pulse wave is obtained continuously and non–invasively. κ is then processed so as to obtain the instantaneous values of the desired parameters.

METHOD AND DEVICE FOR CONTINUOUS ANALYSIS OF CARDIOVASCULAR ACTIVITY OF A SUBJECT

FIELD OF THE INVENTION

The invention is in the field of medical diagnostic devices and more specifically devices for analyzing cardiovascular activity of a subject.

5 **GLOSSARY**

There follows a glossary of terms used herein, some of which are standard, others having been coined, together with their abbreviations.

Plethysmograph (PG) - An instrument for measuring blood flow.

10

Pulse Transit Time (PTT) – The elapsed time between the arrival of a pulse pressure peak at two points in the arterial system, or the elapsed time between a particular point in the ECG signal and the arrival of the consequent pulse wave at a particular point in the arterial system.

15

Cardiac output (CO) - The blood volume pumped into the aorta by the heart per minute.

Vascular compliance (VCL) - The ratio of the change in the blood vessel
20 volume to the change in pressure.

AREA - The area under the peak of a plethysmograph signal.

Peak Amplitude (PA) - The amplitude of the peak of a plethysmograph signal.

Systolic Pressure (SP) - The blood pressure during the

5   contraction phase of the cardiac cycle.

Diastolic Pressure (DP) - The blood pressure during the relaxation period of the cardiac cycle.

10 **BACKGROUND OF THE INVENTION**

Continuous, non-invasive monitoring of blood pressure and vascular parameters is important, for example, in people for whom abnormally high or low blood pressure poses a major threat to their health. Several approaches have been developed for noninvasive, continuous, blood pressure

15 monitoring. For example, U.S. Patent 4,475,554 discloses a device which determines blood pressure from oscillometric measurements. These devices utilize an inflatable cuff that can be placed on an arm above the elbow or on a finger. The cuff is inflated to equilibrate with the internal pressure in the underlying digital vessels. As the blood pressure in the digital arteries

20 fluctuates, the cuff pressure is adjusted by a feedback control mechanism so as to balance the blood pressure. The blood pressure at any moment is considered to be proportional to the cuff pressure. This assumes that the elasticity and tone of the digital arteries remains constant over time while in fact it is extremely variable. For this reason, these devices are not practical for prolonged blood

25 pressure monitoring. Moreover, the constant cuff pressure makes these cuffs uncomfortable for the patient and often causes problems in the peripheral blood circulation. These oscillometric devices are therefore rarely used for continuous blood pressure monitoring.

Several studies have attempted to estimate systolic and diastolic

30 pressure by analyzing only the plethysmograph (PG) signal. These methods, however, employ high order derivatives and therefore require a signal with

extremely low noise that is practically unattainable due to the subject's movements. Moreover, these methods cannot be used for real time blood pressure measurements since the data must be averaged over several minutes.

US patents 4,869,262 to Orr, 4,807,638 to Sramek, and 5,709,212 to Sugo, disclose devices that calculate blood pressure only from pulse transient time (PTT). The reliability and reproducibility of blood pressure measurements determined solely from PTT, however, is not great enough to allow accurate blood pressure measurements.

Another approach to non-invasive monitoring of blood pressure is disclosed in European Patent Application EP 0 443 267 A1 of Smith. This method uses both the PG signal and a PTT for the calculation of the systolic and diastolic pressures. The PG signal must first be normalized in each cardiac cycle by dividing the AC signal by the DC signal assuming that the variation in vascular tone and elasticity is slower than that in the heart rate. This normalization procedure is empirical and inaccurate. Moreover, the equations used for calculating the systolic and diastolic pressures are also empirical and thus inaccurate in many cases.

It has long been known that changes in cardiac output and other vascular characteristics (compliance, resistance, and Young modulus) affect blood pressure. Different physiological processes govern blood pressure changes of different origins and a different medical treatment is required for the same change in blood pressure when it arises from different origins. Determining the cause of a change in blood pressure is therefore crucial for successful treatment. However none of the prior-art devices and methods discloses means for the non-invasive monitoring of these factors. Moreover, all of the prior-art devices and methods ignore the effects of these factors on blood pressure.

There is accordingly a need in the art for a method and device for the non-invasive, continuous monitoring of blood pressure, cardiac output, and other vascular characteristics in which the disadvantages of the aforementioned prior-art methods are substantially reduced or eliminated.

REFERENCES

US Patents

5   US 4,475,554   10/1984   Hyndman

US 4,807,638   2/1989   Sramek

US 4,869,262   9/1989   Orr

US 5,709,212   1/98   Sugo

European Patent Application

10   EP 0 443 267 A1 (Corresponding to US 484687) 2/1990   Smith

SUMMARY OF THE INVENTION

In the context of the present invention, two explicitly described,
15 calculable or measurable variables are considered equivalent to each other
when the two variables are proportional to each other.

In the following description and set of claims, κ will be used to
denote the ratio of the blood flow velocity to the propagation speed of the
pressure pulse wave in an individual.

20   The invention is based on the novel and non-obvious finding that
diastolic and systolic blood pressures determined from calculations involving κ
are more accurate than those obtained by prior art methods where κ is not used.

The invention thus comprises a method and a device for the
continuous and non-invasive measurement of κ. In a preferred embodiment of
25 the invention, κ is obtained from a PG signal and PTT of a subject. In a most
preferred embodiment κ is obtained from a PG signal and PTT of a subject
according to the theory of waves of strong discontinuities as described for
example in Landau L.D. and Lifshitz E.M., *Statistical Physics,* Pergamon
Press, 1979; Landau L.D., and Lifshitz E.M., *Fluid Mechanics,* Pergamon
30 Press, 1987; and Landau L.D., Lifshitz E.M., *Theory of Elasticity,* Pergamon
Press, 1986, and Kaplan D. and Glass, *Understanding Non-Linear Dynamics,*

Springer-Verlag, N.Y., 1995, which are hereby incorporated in their entirety by reference. In a yet more preferred embodiment, κ is given by:

$$\kappa = 1/(1/(PEAK \cdot v) + 1),$$

5

where v is the propagation speed of the pulse wave (the pulse wave velocity) which is inversely proportional to PTT, and

$$PEAK = k_1 \cdot PTT \ PA + k_2 \cdot AREA,$$

10

where PA and AREA are respectively the amplitude and area of the pulse wave obtained from the PG signal, and k_1 and k_2 are two empirically obtained constants.

In another preferred embodiment κ is given by: $\kappa = \dfrac{1}{\left(\left(\dfrac{1}{PA}\right)+1\right)}$

15   Slow (0.01-0.05 Hz) fluctuations in vascular radius (vasomotor tone) can optionally be filtered out from the PG signal in order to increase the accuracy of the κ measurement. This can be carried out, for example, by replacing PEAK in the definition of κ with PEAK/(slow component of PEAK)^2. The slow component of PEAK can be obtained, for example, by 20 low-pass filtering of the pulse wave. Other methods for obtaining κ continuously and non-invasively are also contemplated within the scope of the invention.

Means for obtaining the PG signal of a subject continuously and non-invasively is known in the art and may, for example, be a photo-PG sensor. 25 Other methods for measuring pressure waves in a blood vessel are also contemplated within the scope of the invention. This includes, but is not limited to, use of several photo PG devices, impedance PG devices, piezoelectric, ultrasound, laser, or other types of sensors.

Means for the continuous and non-invasive determination of PTT is known in the art and may comprise, for example, an electrocardiograph monitor and a PG sensor. The PTT in this case is the time lapse between a particular point in the ECG wave, for example the R peak, and the arrival of the

5   corresponding pressure wave at the PG sensor. Other means for measuring PTT comprise, for example, a pair of PG sensors that are attached to the skin along the same arterial vessel and separated from one another. In this case, the PPT is the time lapse between the arrival of a pressure wave at the two locations.

The invention thus further provides for a device for processing κ

10   in real time so as to obtain a continuous and non-invasive measurement of systolic and diastolic blood pressures.

Still further, the invention provides for a device for processing κ in real time so as to obtain a continuous and non-invasive measurement of Young modulus, vascular resistance, cardiac output, and vascular compliance.

15   The prior art does not disclose methods for obtaining these parameters.

The measurements provided by the invention of the diastolic and systolic blood pressures, Young modulus, vascular resistance, cardiac output, and vascular compliance are more robust and less sensitive to external noises, changes in body position, and sensor placement than measurements provided

20   by prior art devices.

The invention further provides for a device for processing κ in real time so as to continuously and non-invasively obtain indices for indicating a change in the blood pressure in a subject due to a change in cardiac output or a change in vascular compliance. Since different physiological processes

25   govern blood pressure changes of different origins and a different medical treatment is required for the same change in blood pressure when it arises from different origins, the present invention provides means for determining the appropriate treatment.

In a preferred embodiment, κ is processed in real time so as to

30   obtain the aforementioned parameters according to the theory of waves of

strong discontinuities. In a most preferred embodiment, the aforementioned
parameters are obtained using the following algorithmic expressions:

Systolic Pressure (SP)

5　　Method 1

$$SP = \rho v^2 \Phi(\kappa, \gamma),$$

where ρ is the blood density, γ is the thermodynamic Poisson exponent of the
10　blood, and

$$\Phi = \frac{\sqrt{2\kappa(\gamma-1)^2 + 4\cdot(\gamma-1)+1} - 1}{2(\gamma-1)}$$

Method 2

15

$$SP = (\log v^2)/\alpha + 2\rho\, v^2\kappa/3 + \lambda,$$

where $\lambda = (\log(2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, h is the
thickness of the arterial wall, E_0 is Young modulus referred to zero pressure,
20　and α is an empirically obtained constant.

Method 3

$$SP = (\log v^2/(1 - \varepsilon H^2))/\alpha + 2\rho v^2\kappa/3 + \lambda,$$

25

where ε is an empirically obtained constant and H is the heart rate.

Method 4

$$SP = [(\log v^2)/\alpha + \lambda]/(1 - \kappa).$$

Method 5

$$SP = [(\log v^2/(1 - \varepsilon H^2))/\alpha + \lambda]/(1 - \kappa).$$

5 **Diastolic Pressure (DP)**

$$DP = SP - \rho v^2 \kappa,$$

Young Modulus

10 Method 1

$$E = (2R/h)\ (SP\text{-}DP)/\kappa$$

Method 2

$$E = (2R/h)\ SP/\Phi\ (\kappa,\gamma)$$

15

Method 3

$$E = (2R/h)\ \rho\ \exp[(-\lambda+MP)\alpha]$$

where MP is the mean pressure, $MP = (SP + 2 \cdot DP)/3$, where SP or DP is

20 obtained using an algorithmic expression involving κ.

Method 4

$$E = (2R/h) \cdot \rho \cdot \exp\ ((-\lambda+SP \cdot (1-\kappa))\alpha)$$

25 **Cardiac Output (CO)**

$$CO = PEAK \cdot \{\ v \cdot [1 + SP/(2\rho \cdot v^2)]\}^2$$

where SP is obtained using an algorithmic expression involving κ, and the slow

component of PEAK has been filtered out as described above.

30 **Vascular Resistance (VR)**

$$VR = (SP - DP)/CO.$$

where any one or more of SP, DP, and CO are obtained using an algorithmic expression involving κ.

Vascular Compliance (VC)

$$VC = PEAK/(SP - DP).$$

where any one or more of SP, and DP are obtained from a calculation involving κ. Other methods for obtaining vascular compliance from κ are also contemplated within the scope of the invention.

The Effect of VC, VR and CO on Blood Pressure

The relative contribution of CO to an observed change in SP is given by a parameter INDEX1 defined by

$$INDEX1 = \partial SP/\partial CO - \partial SP/\partial VC$$

where any one or more of the parameters SP, CO, and VC are obtained from a calculation involving κ. An increase in INDEX1 over time is indicative of a change in SP primarily due to changes in cardiac output (CO). A decrease in INDEX1 over time is indicative of a changes in SP primarily due to a change in vascular compliance (VC).

The relative contribution of VR and CO to an observed change in SP is given by a parameter INDEX2 defined by

$$INDEX2 = \partial SP/\partial CO - \partial SP/\partial VR$$

where any one or more of the parameters SP, CO, and VR are obtained from a calculation involving κ. An increase in INDEX2 over time is indicative of a change in SP primarily due to changes in cardiac output (CO). A decrease in INDEX2 over time is indicative of a change in SP and DP primarily due to a change in vascular resistance (VR).

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described by way of example only with reference to the accompanying non-limiting drawings in which:

5   **Fig. 1.** shows one embodiment using a device of the invention; and

Fig. 2 shows a generalized flow chart of the processing steps according to one embodiment of the invention.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

10   Fig. 1 shows a subject **10** being monitored by a device according to a preferred embodiment of the invention. ECG electrodes **12** have been affixed to the subject's chest for continuously and non-invasively monitoring his/her electrocardiograph. A PG sensor **14** has been attached to the subject's finger for continuously and non-invasively monitoring his/her pulse wave.

15   Signals from the ECG electrodes and the PG sensor are continuously fed into a processor **16**. The processor **16** includes an interface, an A/D converter, amplifiers and a cable to a serial port of a PC computer **18**. Preliminary blood pressure measurements are carried out for calibration purposes in order to obtain any empirically defined constants using a commercially available

20   sphygmomanometer **20**.

A generalized flow chart of the processing carried out by processor **16** is shown in Fig 2. The ECG and PG signals are first processed in real time so as to obtain instantaneous values of κ. κ is then processed in real time so as to obtain the instantaneous values of the desired parameters. The

25   calculated values of the desired parameters are transferred in real time to PC **18** for storage and display.

Example

The invention will now be demonstrated by way of a non-limiting

30   example.

Methods

The blood pressure of a group of eleven subjects, 7 males and 4 females ranging in age from 21-44, was examined using the invention. Of the 11 subjects, 10 were known to have normal blood pressure, while one had

5 borderline hypertension. Each subject was examined at least twice. Each examination lasted approximately one hour and included measurements in the following positions: supine (15 min), sitting (15 min), and standing (10 min). In 7 subjects measurements were also made in a sitting position after 10 min of controlled physical exercise on a bicycle or during a Valsalva test. The data

10 were processed separately for each subject and for each position.

Reference blood pressure measurements were obtained from each subject using one or both of the following devices:

1. A commercially available blood pressure measurement device (A Dynapulse 200M™ comprising a cuff-manometer connected

15 to a PC computer).

2. Continuous oscillometric blood pressure measurement from the finger arteries (Finapress™, Ohmeda) combined with a device (Ultramind) for the transmission of the output to a PC computer.

When the Finapress™ device was used as a reference, blood

20 pressure was measured continuously and saved in real time. When the Dynapulse™ device was used, discrete blood pressure measurements were made 3 - 4 times during the examination. The reference blood pressure measurements at the beginning of each examination were used to obtain the constant parameters k_1, k_2

25 ECG and PG signals were obtained from each subject and processed by custom software in real time. Processing included the following successive operations:

1. Smoothing (filtering and high-frequency noise).

2. Baseline drift correlation of the PG signal (high pass filtering

30 using a cut-off frequency of 1.0-2.0 Hz).

3. Performing a peak recognition procedure on the ECG and PG signals.

4. Obtaining PA as the height of the PG peak.

5. Calculating PTT as the time interval between an ECG peak and the corresponding PG peak.

6. Calculating AREA by integration of the PG signal over the time interval from the ECG peak to the PG peak.

7. Calculating the heart rate.

8. Calculating the constant parameters k_1, k_2, α and ε using a chi-square test in accordance with the maximal likelihood principle.

SP and DP were then obtained for each subject as follows:

ECG and PG signals were obtained from each subject and processed by custom software in real time. Processing included the following successive operations:

1. Smoothing (filtering and high-frequency noise).

2. Baseline drift correlation of the PG signal (high pass filtering using a cut-off frequency of 1.0-2.0 Hz).

3. Performing a peak recognition procedure on the ECG and PG signals.

4. Obtaining PA as the height of the PG peak.

5. Calculating PTT as the time interval between an ECG peak and the corresponding PG peak.

6. Calculating AREA by integration of the PG signal over the time interval from the ECG peak to the PG peak.

7. Calculating the heart rate.

8. Calculating SP and DP according to the methods of the invention.

9. Calculating SP and DP according to the method of European Patent Application EPO 443267A1 of Smith.

The constant parameters were adjusted from time to time during the examination as required.

The results were compared with those obtained by the following methods,

The output consisted of the following two parts:

1.   SP and DP time series obtained according to the invention and according to the method of Smith.

2   The mean error and the root-mean-square error between the SP and DP time series and the reference blood pressure measurements.

Results

The blood pressure measurements obtained according to the invention on subjects at rest, and those calculated by the empirical formulas of European Patent Application EPO 443267A1 of Smith (Table 1) were

5   compared with those obtained by the reference devices. SP and DP determinations obtained according to the present invention are more stable than those obtained by the method of Smith. In particular, the mean error and standard deviations of SP measurements obtained after stress according to Methods 3 and 5 of the present invention were 2 and 5 times smaller,

10   respectively, than those obtained by the method of Smith. In all 26 subjects, when SP measurements were obtained according to Method 3 and 5 the mean error was 1.6 times smaller than that obtained by the method of Smith $(p=0.023)$.

Table 2 shows the results of blood pressure measurements

15   obtained on subjects while supine or sitting after exercise. The five methods of the invention and the method of European patent Application EPO 443267A1 of Smith were compared with measurements obtained by Finapress™ and a Dynapulse 200M™. In particular, the mean error between SP measurements obtained according to Methods 3 and 5 in all 26 subjects was 54% of the error

20   obtained of Smith $(p=0.023)$.

Table 1

Subject's position		Method 1	Methods 2, 4	Methods 3, 5	Smith
Dynapulse™ (n=12)	SP	18±13	13±8	10±8	20±37
	DP	11±8	7±5	6±4	8±4
Finapress™ (n=14)	SP	12±5	9±4	8±4	9±4
	DP	7±3	6±3	8±4	6±3

25   **Table 1.** Mean error ± standard deviation (mm Hg) between the blood pressure measurements obtained by the five methods of the present invention, and the

method of Smith compared with measurements obtained using a Finapress™ or Dynapulse™.

Table 2

Subject's position		Method 1	Methods 2, 4	Methods 3, 5	Smith
Supine, (n=19)	SP	11±5	9±4	7±4	8±4
	DP	7±4	6±4	7±4	6±3
Sitting, following exercise (n=7+)	SP	23±14	17±8	14±9	30±47
	DP	14±8	7±4	7±4	8±4
Total (n=26)	SP	15±10	11±6	9±6	14±26
	DP	9±6	6±4	7±4	7±3

Table 2. Mean error ± standard deviation (mm Hg) obtained by the five methods of the present invention and the method of Eurpean Patent Application EPO 443267A1 of Smith compared with measurements obtained using a Finapress™ and a Dynapulse 200M™. The measurements were made while the subject was either supine with no prior exercise or sitting following exercise.

The present invention has been described with a certain degree of particularity, but it should be understood that various notifications and alterations may be made without departing from the scope or spirit of the invention as defined by the following claims:

CLAIMS

1.   A method for obtaining continuously and non-invasively one or more of the parameters of a subject from the list comprising:

     i.   systolic blood pressure,

     ii.   diastolic blood pressure,

     iii.   Young modulus of an artery,

     iv.   cardiac output,

     v.   relative changes in vascular resistance, and

     vi.   relative changes in vascular compliance;

said method comprising:

     (a)   substantially obtaining continuously and non-invasively the ratio, κ, of the subject's blood flow velocity to the propagation speed of the subject's pulse wave; and

     (b)   processing κ substantially in real time so as to obtain the instantaneous values of the desired parameters.

2.   The method according to Claim 1 wherein κ is obtained by processing a PG signal and a PTT continuously and non-invasively obtained from the subject.

3.   The method of Claim 2 wherein κ is obtained according to the following algorithmic expression:

$$\kappa = 1/(1/(PEAK \cdot v) + 1),$$

where v is the pulse velocity, and

$$PEAK = k_1 \cdot PTTPA + k_2 \cdot AREA,$$

where PA and AREA are respectively the amplitude and area of the pulse wave obtained from the PG signal, and k_1 and k_2 are obtained empirically.

4.   The method of Claim 2, wherein κ is obtained according to the following algorithm expression:

$$\kappa = \cfrac{1}{\left(\left(\cfrac{1}{PA}\right)+1\right)}$$

where PA is the amplitude of the pulse wave obtained from the PG signal.

5.   The method of Claims 3 and 4 further comprising filtering out slow fluctuations in the pulse wave.

6.   The method of Claim 5 wherein slow fluctuations in PEAK are filtered out by replacing PEAK in Claim 3 with PEAK/(slow component of PEAK)^2

7.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = \rho v^2 \Phi(\kappa, \gamma),$$

where ρ is the blood density, γ is the thermodynamic Poisson exponent of the blood, v is the pulse wave velocity and

$$\Phi = \frac{\sqrt{2\kappa(\gamma-1)^2 + 4\cdot(\gamma-1)+1}-1}{2(\gamma-1)}$$

8.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = (\log v^2)/\alpha + 2\rho\, v^2\kappa/3 + \lambda,$$

where ρ is the blood density, v is the pulse wave velocity, and λ = (log $(2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, h is the thickness of the arterial wall and α is obtained empirically.

18

9. The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = [(\log v^2)/\alpha + \lambda]/(1 - \kappa)$$

where v is the pulse wave velocity and $\lambda = (\log (2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, ρ is the blood density, h is the thickness of the arterial wall and α is obtained empirically.

10. The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = (\log v^2/(1 - \varepsilon H^2))/\alpha + 2\rho v^2 \kappa/3 + \lambda$$

where ρ is the blood density, v is the pulse wave velocity, H is the heart rate, $\lambda = (\log (2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, h is the thickness of the arterial wall and ε and α are obtained empirically.

11. The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = [(\log v^2/(1 - \varepsilon H^2))/\alpha + \lambda]/(1 - \kappa),$$

where, v is the pulse wave velocity, H is the heart rate, $\lambda = (\log (2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, h is the thickness of the arterial wall, ρ is the blood density, and ε and α are obtained empirically.

12. The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the subject's diastolic blood pressure includes the algorithmic expression

$$DP = SP - \rho v^2 \kappa,$$

where SP is the systolic pressure, ρ is the blood density, and v is the pulse wave velocity.

13.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h) (SP\text{-}DP)/\kappa$$

where R is the radius of the artery, h is the thickness of the arterial wall, SP is the systolic pressure and DP is the diastolic pressure.

14.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h) SP/\Phi (\kappa,\gamma)$$

where R is the radius of the artery, h is the thickness of the arterial wall, SP is the systolic pressure, γ is the thermodynamic Poisson exponent of the blood and

$$\Phi = \frac{\sqrt{2\kappa(\gamma-1)^2 + 4\cdot(\gamma-1)+1} - 1}{2(\gamma-1)}$$

15.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h)\cdot\rho\cdot\exp(-\lambda + MP)\alpha$$

where R is the radius of the artery, h is the thickness of the arterial wall, ρ is the blood density, $MP = (SP + 2\cdot DP)/3$ where SP is the systolic pressure, DP is the diastolic pressure wherein at least one of the systolic pressure or the diastolic pressure is obtained using an algorithmic expression involving κ, and $\lambda = (\log (2\rho R/E_o h))/\alpha$ where E_o is Young modulus referred to zero pressure and α is an empirically obtained constant.

16.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h) \cdot \rho \cdot \exp\left((-\lambda + SP \cdot (1-\kappa))\alpha\right)$$

where R is the radius of the artery, h is the thickness of the artery wall, ρ is the blood density, SP is the systolic pressure and $\lambda = (\log(2\rho R/E_o h))/\alpha$, wherein E_o is Young Modulus referred to zero pressure and α is an empirically obtained

5 constant.

17.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the relative change in the cardiac output of a subject includes the algorithmic expression

10                      $$CO = PEAK \cdot \{v \cdot [1 + SP/(2\rho \cdot v^2)]\}^2$$

where SP is a systolic pressure obtained using an algorithmic expression involving κ, ρ is the blood density, and v is the pulse wave velocity and

15                      $$PEAK = k_1 \cdot PTT \cdot PA + k_2 \cdot AREA,$$

where PA and AREA are respectively the amplitude and area of the pulse wave peak obtained from a PG signal, and k_1 and k_2 are obtained empirically.

18.   The method of Claim 14 further comprising filtering out slow
20 fluctuations in the pulse wave.

19.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the subject's cardiac resistance includes the algorithmic expression

$$VR = (SP - DP)/CO.$$

25 where any one or more of SP, DP, and CO are obtained from a calculation involving κ.

20.   The method of Claim 1, wherein the processing stipulated in step (a) for the calculation of the relative change in the vascular compliance of a subject includes the algorithmic expression

30                      $$VC = PEAK/(SP - DP),$$

Where

$$PEAK = k_1 \cdot PTT \cdot PA + k_2 \cdot AREA,$$

where PA and AREA are respectively the amplitude and area of the pulse wave obtained from the PG signal, and k_1 and k_2 are obtained empirically.

21.   A method for determining continuously and non-invasively whether a change in a subject's blood pressure is due to a change in cardiac output or vascular compliance, comprising:

(a)   substantially obtaining continuously and non-invasively the ratio, κ of the subject's blood flow velocity to the propagation speed of the subject's pulse wave;

(b)   processing κ substantially in real time so as to obtain the instantaneous values of the subject's SP, CO and VC; and

(c)   processing the subject's SP, CO, and VC in real time so as to obtain the instantaneous values of the algorithmic expression:

$$INDEX1 = \partial SP/\partial CO - \partial SP/\partial VC,$$

an increase in INDEX1 over time indicating a change in the subject's blood pressure due to a change in cardiac output, otherwise the change in the subject's blood pressure is due to a change in vascular compliance.

22.   A method for determining continuously and non-invasively whether a change in a subject's blood pressure is due to a change in the subject's cardiac output or vascular resistance, comprising:

(a)   substantially obtaining continuously and non-invasively the ratio, κ of the subject's blood flow velocity to the propagation speed of the subject's pulse wave;

(b)   processing κ substantially in real time so as to obtain the instantaneous values of the subject's SP, CO and VR; and

(c)   processing the subject's SP, CO, and VR in real time so as to obtain the instantaneous values of the algorithmic expression:

$$INDEX2 = \partial SP/\partial CO - \partial SP/\partial VR$$

an increase in INDEX2 over time indicating a change in the subject's blood pressure due to a change in cardiac output, otherwise the change in the subject's blood pressure is due to a change in vascular resistance.

23.　　　　　A device for obtaining continuously and non-invasively one or
5　more of the vascular parameters of a subject from the list comprising:

i.　　　systolic blood pressure,

ii.　　diastolic blood pressure,

iii.　Young's modulus of an artery,

iv.　relative change in cardiac output,

10　v.　　relative change in vascular resistance, and

vi.　relative changes in vascular compliance;

said device comprising:

(a)　　a device substantially obtaining continuously and non-invasively
the ratio, κ of the subject's blood flow velocity to the propagation speed of the
15　subject's pulse wave; and

(b)　　a device processing κ substantially in real time so as to obtain the
instantaneous values of the desired parameters.

24.　　　　　The device according to Claim 23 wherein κ is obtained by
processing a PG signal and a PTT continuously and non-invasively obtained
20　from the subject.

25.　　　　　The device of Claim 24 wherein κ is obtained according to the
following algorithmic expression:

$$\kappa = 1/(1/(PEAK \cdot v) + 1),$$

25

where v is inversely proportional to PTT, and

$$PEAK = k_1 \cdot PTT \cdot PA + k_2 \cdot AREA,$$

30　where PA and AREA are respectively the amplitude and area of the pulse wave
obtained from the PG signal, and k_1 and k_2 are obtained empirically.

26.   The device according to Claim 23, wherein κ is obtained according to the following algorithmic expression

$$\kappa = 1/((1/PA) + 1)$$

where PA is the amplitude of the pulse wave obtained from the PG signal.

5   27.   The device of Claim 25 capable of filtering out slow fluctuations in the pulse wave.

28.   The device of Claim 27 wherein slow fluctuations in the pulse wave are filtered out by replacing PEAK in Claim 22 with PEAK/(slow component of PEAK)^2

10   29.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = \rho v^2 \Phi(\kappa, \gamma),$$

where ρ is the blood density, γ is the thermodynamic Poisson exponent of the

15   blood, v is the pulse wave velocity and

$$\Phi = \frac{\sqrt{2\kappa(\gamma-1)^2 + 4\cdot(\gamma-1)+1} - 1}{2(\gamma-1)}$$

30.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

20                   $$SP = (\log v^2)/\alpha + 2\rho\, v^2\kappa/3 + \lambda,$$

where ρ is the blood density, and $\lambda = (\log 2\rho R/E_0 h)/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, h is the thickness of the arterial wall and α is obtained empirically.

31.   The device of Claim 23, wherein the processing stipulated in step

25   (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = [(\log v^2)/\alpha + \lambda]/(1 - \kappa)$$

where v is the pulse wave velocity and $\lambda = (\log (2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, ρ is the

blood density. h is the thickness of the arterial wall and α is obtained empirically.

32.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = (\log v^2/(1 - \varepsilon H^2))/\alpha + 2\rho v^2 \kappa/3 + \lambda$$

where ρ is the blood density, v is the pulse wave velocity, H is the heart rate, $\lambda = (\log (2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, h is the thickness of the arterial wall and ε and α are obtained empirically.

33.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of the subject's systolic blood pressure includes the algorithmic expression

$$SP = [(\log v^2/(1 - \varepsilon H^2))/\alpha + \lambda]/(1 - \kappa),$$

where, v is the pulse wave velocity, H is the heart rate, $\lambda = (\log (2\rho R/E_0 h))/\alpha$, where R is the radius of the artery, E_0 is Young modulus referred to zero pressure, h is the thickness of the arterial wall, ρ is the blood density, and ε and α are obtained empirically.

34.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of the subject's diastolic blood pressure includes the algorithmic expression

$$DP = SP - \rho v^2 \kappa,$$

where SP is the systolic pressure ρ is the blood density, and v is the pulse wave velocity.

35.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h) (SP-DP)/\kappa$$

where R is the radius of the artery, h is the thickness of the arterial wall, SP is the systolic pressure and DP is the diastolic pressure.

36.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h)\ SP/\Phi\ (\kappa,\gamma)$$

where R is the radius of the artery, h is the thickness of the arterial wall, SP is the systolic pressure, γ is the thermodynamic Poisson exponent of the blood and

$$\Phi = \frac{\sqrt{2\kappa(\gamma-1)^2 + 4\cdot(\gamma-1)+1}-1}{2(\gamma-1)}$$

37.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h)\cdot\rho\cdot\exp\ (-\lambda+MP)\alpha$$

where R is the radius of the artery, h is the thickness of the arterial wall, ρ is the blood density, $MP = (SP + 2\cdot DP)/3$ where SP is the systolic pressure, DP is the diastolic pressure wherein at least one of the systolic pressure or the diastolic pressure is obtained using an algorithmic expression involving κ, and $\lambda = (\log\ (2\rho R/E_0 h))/\alpha$ where E_0 is Young modulus referred to zero pressure and α is an empirically obtained constant.

38.   The device of Claim 35, wherein the processing stipulated in step (a) for the calculation of Young modulus of an artery of the subject includes the algorithmic expression

$$E = (2R/h)\cdot\rho\cdot\exp\ ((-\lambda+SP\cdot(1-\kappa))\alpha$$

where R is the radius of the artery, h is the thickness of the artery wall, ρ is the blood density, SP is the systolic pressure and $\lambda = (\log\ (2\rho R/E_0 h))/\alpha$, wherein E_0 is Young Modulus referred to zero pressure and α is an empirically obtained constant.

39.   The device of Claim 23, wherein the processing stipulated in step (a) for the calculation of the relative change in the cardiac output of a subject includes the algorithmic expression

5
$$CO = PEAK \cdot \{v \cdot [1 + SP/(2\rho \cdot v^2)]\}^2$$

where SP is a systolic pressure obtained using an algorithmic expression involving κ and

10
$$PEAK = k_1 \cdot PTT \cdot PA + k_2 \cdot AREA,$$

where PA and AREA are respectively the amplitude and area of the pulse wave obtained from a PG signal, and k_1 and k_2 are obtained empirically.

40.   The device of Claim 23, wherein the processing stipulated in step
15   (a) for the calculation of the subject's cardiac resistance includes the algorithmic expression

$$VR = (SP - DP)/CO.$$

20   where any one or more of SP, DP, and CO are obtained from a calculation involving κ.

41.   A device determining continuously and non-invasively whether a change in a subject's blood pressure is due to a change in cardiac output or vascular compliance, comprising:

25   (a)   a device substantially obtaining continuously and non-invasively the ratio, κ of the subject's blood flow velocity to the propagation speed of the subject's pulse wave;

(b)   a device processing κ substantially in real time so as to obtain the instantaneous values of the subject's SP, CO and VC; and

27

(c)   a device processing the subject's SP, CO, and VC in real time so as to obtain the instantaneous values of the algorithmic expression:

$$INDEX1 = \partial SP/\partial CO - \partial SP/\partial VC,$$

an increase in INDEX1 over time indicating a change in the subject's blood
5   pressure due to a change in cardiac output, otherwise the change in the subject's blood pressure is due to a change in vascular compliance.

42.   A device determining continuously and non-invasively whether a change in a subject's blood pressure is due to a change in the subject's vascular resistance comprising:

10   (a)   a device substantially obtaining continuously and non-invasively the ratio, κ of the subject's blood flow velocity to the propagation speed of the subject's pulse wave;

(b)   a device processing κ substantially in real time so as to obtain the instantaneous values of the subject's SP, CO and VR; and

15   (c)   a device processing the subject's SP, CO, and VR in real time so as to obtain the instantaneous values of the algorithmic expression:

$$INDEX2 = \partial SP/\partial CO - \partial SP/\partial VR,$$

an increase in INDEX2 over time indicating a change in the subject's blood pressure due to a change in cardiac output, otherwise the change in the
20   subject's blood pressure is due to a change in vascular resistance.

FIG.1

2/2

```
┌─────────────────────────┐
│   OBTAIN THE ECG        │
│   AND PC SIGNALS        │
└─────────────────────────┘
            │
            │
┌─────────────────────────┐
│      CALCULATE          │
│         K               │
└─────────────────────────┘
            │
            │
┌─────────────────────────┐
│   CALCULATE FROM        │
│   K THE PARAMETERS      │
│   OF INTEREST           │
└─────────────────────────┘
            │
            │
┌─────────────────────────┐
│   TRANSFER THE          │
│   RESULTS OF THE        │
│   CALCULATIONS TO PC    │
│   FOR STORAGE AND/OR    │
│   DISPLAY               │
└─────────────────────────┘
```

FIG.2

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   A61B5/0285   A61B5/0225

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   A61B   G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 309 916 A (HATSCHEK RUDOLF A) 10 May 1994 (1994-05-10) abstract	1-42
A	WO 98 25516 A (DXTEK INC) 18 June 1998 (1998-06-18) claim 1	1-42
A	EP 0 443 267 A (SENTINEL MONITORING INC) 28 August 1991 (1991-08-28) cited in the application abstract; figure 1	1-42
A	EP 0 824 009 A (COLIN CORP) 18 February 1998 (1998-02-18) abstract	1-42

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 May 2000	22/05/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Jonsson, P.O.

Form PCT/ISA/210 (second sheet) (July 1992)

2

INTERNATIONAL SEARCH REPORT

information on patent family members

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5309916	A	10-05-1994	AT	132720 T	15-01-1996
			DE	59107232 D	22-02-1996
			EP	0467853 A	22-01-1992
			JP	2750023 B	13-05-1998
			JP	4250135 A	07-09-1992
WO 9825516	A	18-06-1998	US	5865755 A	02-02-1999
			AU	4755697 A	03-07-1998
			CN	1237885 A	08-12-1999
			EP	0944352 A	29-09-1999
			US	5857975 A	12-01-1999
EP 0443267	A	28-08-1991	CA	2036900 A	24-08-1991
			JP	6014891 A	25-01-1994
EP 0824009	A	18-02-1998	NONE		